However, recently, large phase III trials in advanced prostate and breast cancer have shown significant improvement in progression-free survival by the addition of the AKT inhibitors ipatasertib [55] and capivasertib [56] to standard treatments. This evidence concerns the gene AKT1 and breast cancer.